DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality
Authors
Keywords
-
Journal
Blood Advances
Volume 4, Issue 13, Pages 3024-3033
Publisher
American Society of Hematology
Online
2020-07-02
DOI
10.1182/bloodadvances.2020001972
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Infectious Complications in Aggressive B Cell Non-Hodgkin Lymphoma after CD-19 Chimeric Antigen Receptor T Cell Therapy
- (2020) Kitsada Wudhikarn et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery
- (2020) Victoria Gutgarts et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
- (2020) Loretta J. Nastoupil et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells
- (2019) Philipp Karschnia et al. BLOOD
- Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study
- (2019) Stephen J. Schuster et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Thirty Day Resource Utilization after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies
- (2019) Gunjan L. Shah et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
- (2019) Ana Cordeiro et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34 + -Selected Allogeneic Hematopoietic Cell Transplantation
- (2018) Michael Scordo et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Impact of Toxicity on Survival for Older Adult Patients after CD34 + Selected Allogeneic Hematopoietic Stem Cell Transplantation
- (2018) Gunjan L. Shah et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience
- (2018) Danielle S. Burstein et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
- (2018) Jae H Park et al. CLINICAL INFECTIOUS DISEASES
- Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities
- (2018) Gunjan L. Shah et al. Current Hematologic Malignancy Reports
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities
- (2018) Rajshekhar Chakraborty et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T-cell therapies for lymphoma
- (2017) Jennifer N. Brudno et al. Nature Reviews Clinical Oncology
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started